Therorna Inc.
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Therorna Inc. is a clinical-stage biotechnology company pioneer in circular RNA (circRNA) filed. Built on its proprietary splint-free enzymatic circularization platform and targeted LNP delivery technology, the company develops innovative circRNA-based therapies to address high unmet medical needs in oncology and autoimmune diseases. As a global leader in this field, Therorna successfully completed the world’s first circRNA clinical trial in 100 healthy volunteers, followed by the world’s first IND-approved circRNA oncology therapy. To efficiently advance clinical development, Therorna has established a 16,000 sq ft in-house GMP production facility with robust, end-to-end manufacturing capabilities. The company is aggressively advancing its pipeline, highlighted by its innovative in vivo CAR-T platform, with a lead asset currently in an IIT trail, alongside an ongoing Phase I clinical trial for a cancer vaccine.
Company HQ City:
Beijing & Shanghai;
Company HQ State:
Beijing & Shanghai;
Company HQ Country:
China
Year Founded:
2021
Lead Product in Development:
TI-0032-Anti-CD19 in vivo CAR T; TI-0093 – HPV16+ Cancer Vaccine
CEO
Dr. Lu Gao
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
Nov. 2026
What is your next catalyst (value inflection) update?
The release of interim clinical data from the ongoing IIT trial for TI-0032 (in vivo CAR-T)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}